



Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors

Sean R. Donohue^{a,b,*}, Katarina Varnäs^b, Zhisheng Jia^b, Balázs Gulyás^b, Victor W. Pike^a, Christer Halldin^b

^a Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA

^b Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital, S-17176 Stockholm, Sweden

ARTICLE INFO

Article history:

Received 27 July 2009

Revised 26 August 2009

Accepted 31 August 2009

Available online 3 September 2009

Keywords:

SPECT

PET

CB₁ receptors

Radiiodination

Radioligand

ABSTRACT

There is strong interest to study the involvement of brain cannabinoid subtype-1 (CB₁) receptors in neuropsychiatric disorders with single photon emission computed tomography (SPECT) and a suitable radioligand. Here we report the synthesis of a novel high-affinity radioiodinated CB₁ receptor ligand ([¹²⁵I]**8**, [¹²⁵I]1-(2-iodophenyl)-4-cyano-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxylate, [¹²⁵I]SD7015). By autoradiography in vitro, [¹²⁵I]**8** showed selective binding to CB₁ receptors on human brain postmortem cryosections and now merits labeling with iodine-123 for further evaluation as a SPECT radioligand in non-human primate.

© 2009 Elsevier Ltd. All rights reserved.

Cannabis sativa (marijuana) is one of the oldest known plant derived-therapeutics, owing mainly to its anti-nociceptive properties.¹ Other beneficial effects of cannabis intake may include anti-emesis and appetite stimulation. Conversely, the accompanying psychological 'high' and memory impairment have limited its therapeutic value. The most abundant and psychoactive cannabinoid, Δ⁹-tetrahydrocannabinol (Δ⁹-THC, **1**), binds with high affinity to two known body receptor systems. These receptors have been named cannabinoid subtype-1 (CB₁) and cannabinoid subtype-2 (CB₂).^{2–4} CB₁ receptors have high-densities in brain and are implicated in a number of neuropsychiatric disorders⁵ such as, schizophrenia^{6,7} and depression.^{8,9} CB₂ receptors are located mainly in the periphery and are of less interest to neuropsychiatric research.^{10,11}

Ability to image and measure brain CB₁ receptors non-invasively with radiation computed tomography would assist neuropsychiatric research and drug development. The development of radioligands suitable for imaging brain CB₁ receptors is therefore of strong importance. Recently, there has been a great deal of progress in the development of useable radioligands for positron emission tomography (PET). Some of the more notable PET radioligands (Fig. 1) are [¹¹C]MePPEP ([¹¹C]**2**),^{12,13} [¹⁸F]PipISB ([¹⁸F]**3**),^{14,15} [¹⁸F]MK-9470 ([¹⁸F]**4**),^{16,17} (–)-[¹¹C]SD5014 ((–)-[¹¹C]**5**),¹⁸ [¹¹C]-OMAR ([¹¹C]**6**),^{19,20} and [¹¹C]JHU75575 ([¹¹C]**7**).^{20,21} In comparison,

the development of radioligands for more widespread single-photon computed tomography (SPECT) is much less advanced. Due to the longer half-life of radioiodine for SPECT imaging (e.g., ¹²³I, *t*_{1/2} = 13.2 h), an on-site cyclotron is not required for radiolabeling, as with PET, which allows for more widespread use in pharmaceutical, academic, and hospital settings. Here we report the synthesis, receptor screening, radiiodination, and in vitro autoradiographic evaluation of a novel radioiodinated CB₁ receptor radioligand ([¹²⁵I]4-cyano-1-(2-iodophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide, [¹²⁵I]**8**, [¹²⁵I]SD 7015). Our results strongly suggest that [¹²³I]**8** would merit evaluation as a SPECT radioligand in vivo.

Compound **8** was synthesized according to the procedure depicted in Scheme 1. Conversion of 2-iodoaniline into a diazonium salt, followed by treatment with ethyl 2-chloroacetoacetate in ethanol–water solution under basic conditions gave chloro[(2-iodophenyl)hydrazono]ethyl acetate (**9**). Heating of a solution of **9**, 4-methoxybenzoylacetone nitrile and *N,N*-diisopropylethylamine in *tert*-butanol to reflux gave **10** in low but adequate yield. Hydrolysis of **10** with LiOH in aq-tetrahydrofuran gave the corresponding carboxylic acid, which was then converted into the acyl chloride with oxalyl chloride and a catalytic amount of *N,N*-dimethylformamide. The synthesis of **8** was completed by coupling the acyl chloride with 1-aminopiperidine under basic conditions.

The trimethylstannylated precursor, **11**, required for radiolabeling, was synthesized by refluxing a solution of the known bromo compound **7**²⁰ and hexamethylditin in the presence of palladium catalyst (Scheme 2).

* Corresponding author at present address: Johns Hopkins PET Center, Division of Nuclear Medicine, Radiology, Johns Hopkins Medicine, Nelson B1-122, 600 North Wolfe Street, Baltimore, MD 21287-0816, USA. Tel./fax: +1 410 614 0110.

E-mail address: Sean_Donohue@tracer.nm.jhu.edu (S.R. Donohue).





Figure 1. Structures of [¹¹C]2, [¹⁸F]3, [¹⁸F]4, [¹¹C]5–7, and [¹²⁵I]8. Asterisks denote positions of radiolabels.




Scheme 1. Synthesis of **8**. Reagent, conditions and yields: (a) concentrated HCl, NaNO₂, ethyl 2-chloroacetoacetate, NaOAc, EtOH–H₂O, 16 h, 72%; (b) 4-methoxybenzoyl acetonitrile, DIPEA, *tert*-BuOH, reflux, 16 h, 6%; (c) aq-LiOH, THF, 65 °C, 4 h; (d) DMF_(cat), (COCl)₂, DCM; (e) 1-aminopiperidine, DIPEA, DCM, 2 h, 73%.

A radioligand for imaging brain CB₁ receptors would ideally possess adequately high affinity and moderate lipophilicity to promote rapid development of a high ratio of receptor-specific binding to non-specific binding in brain *in vivo*, that might then allow accurate computation of output measures, such as binding potential.^{22,23} CB₁ receptors are one of the most abundant G protein-coupled receptors in brain, reaching a concentration (B_{max}) of 1752 fmol/mg protein (175 nM) in rat cerebellum.²⁴ Generally, a SPECT radioligand should show a substantial B_{max}/K_d value (>5) to be successful. Hence, an effective CB₁ receptor radioligand might require only a moderately high affinity (K_i or K_d <35 nM). Ligand **8** was found to have about 10-fold higher affinity (3.4 nM; Table 1) than perhaps needed. Calculated ligand lipophilicity ($cLog D_{7.4}$) can be an important predictor of blood–brain barrier penetration and brain non-specific binding. Moderate lipophilicity ($cLog D_{7.4}$ in the range 2.0–3.5) is usually preferred for adequate brain entry without incurring excessive non-specific binding in brain.²³ However, when target binding sites exist in high concentration, higher lipophilicity may be tolerated. For example, [¹¹C]MePPEP is a successful PET radioligand for brain CB₁ receptors despite having a high $cLog D_{7.4}$ value of 5.42.^{12,13} The $cLog D_{7.4}$ value of **8** is 4.14 and appears more favorable for a radioligand than that of [¹¹C]MePPEP. Furthermore, the physicochemical and pharmacologi-

cal properties of **8** compare well with other successful PET radioligands.^{20,21} Therefore, ligand **8** presents acceptable CB₁ receptor affinity and lipophilicity for development as a SPECT radioligand (Table 1).

In addition to acceptable binding affinity and lipophilicity a candidate SPECT radioligand should be selective for binding to the target protein. Ligand **8**, at 10 μM concentration, showed <50% inhibition ($n = 4$) of radioligand binding to the sites: 5-HT_{1B-E}, 5-HT_{2A-C}, 5-HT₃, 5-HT_{5A}, 5-HT₆, 5-HT₇, α_{1A,B}, α_{2A,B}, β₁₋₃, D₁₋₄, DOR, H₁₋₄, M₁₋₅, NET, SERT, σ_{1,2}, V_{1A,1B,2}. K_i values ($n = 3$) of 93.5 ± 20.4 nM (5-HT_{1A}), >10,000 nM (α_{2C}), 1477 ± 148 nM (KOR), 1496 ± 216 nM (MOR), and 3166 ± 586 nM (TSPO) were found. Details of the employed binding assays may be found at the NIMH PDSP web site: <http://pdsp.med.unc.edu>. Hence, **8** was found to have excellent CB₁ receptor selectivity for development as a SPECT radioligand.


[¹²⁵I]**8** was prepared by [¹²⁵I]iodo-destannylation of the corresponding trimethylstannyl precursor (**11**) with [¹²⁵I]NaI and chloramine-T (oxidizer) in methanol (Scheme 2). The crude product was purified with high-performance liquid chromatography (HPLC) as described in Supplementary data. The decay-corrected radiochemical yield of [¹²⁵I]**8** ranged from 48% to 59%. The specific radioactivity of [¹²⁵I]**8** was 81.4 GBq/μmol and the radio-



Scheme 2. Radiosynthesis of [¹²⁵I]**8**. Reagents, conditions and yields: (a) hexamethylditin, Pd(PPh₃)₄, toluene, 20 h, 32%; (b), chloramine-T, aq-HCl, 5 min, 48–59%.

Table 1

K_i values for CB₁ and CB₂ receptors, selectivities for CB₁ versus CB₂ receptors and calculated lipophilicities



Ligand	CB ₁ K_i^a (nM)	CB ₂ K_i^a (nM)	CB ₁ versus CB ₂ selectivity ^a	cLog $D_{7,4}^b$
Rimonabant	1.38 ± 0.17	927 ± 66	672 ± 94	6.01
8	3.40 ± 0.43	548 ± 23	161 ± 47	4.14

^a Values represent mean ± SD of three determinations.

^b cLog $D_{7,4}$ values were calculated using Advanced Chemistry Development (ACD) 9.2.

chemical purity >98%. [¹²⁵I]**8** was thus obtained in adequate yield and purity for further evaluation with sensitive postmortem autoradiography in vitro. Furthermore, these conditions would be applicable to labeling **8** with iodine-123 for evaluation in SPECT imaging.

CB₁ receptors are spread heterogeneously in brain, with high-densities appearing in substantia nigra, globus pallidus, amygdala, cortical regions, and striatum.^{25,26} Brain regions with low CB₁ receptor densities are thalamus, pons, and white matter. In post-

mortem autoradiography in vitro, [¹²⁵I]**8** bound substantially to human brain regions with high CB₁ receptor densities (Fig. 2; panels A, C, E, and G) with highest binding in globus pallidus and substantia nigra (Fig. 2; panels A and E). Additionally [¹²⁵I]**8** showed much lower binding in brain regions with low CB₁ receptor density, including thalamus (Fig. 2; panels C and E). Under conditions in which the CB₁ receptors were blocked with the selective CB₁ ligand, rimonabant (10 μM), the binding of [¹²⁵I]**8** in CB₁ rich regions was greatly reduced and the distribution of radioligand became more homogeneous (Fig. 2, panels B, D, F, and H). Therefore, the regional selectivity of [¹²⁵I]**8** indicated that ¹²³I-labeled **8** would be promising for imaging brain CB₁ receptors with SPECT.

Ligand **8** demonstrated high affinity and good selectivity for CB₁ receptors. [¹²⁵I]**8** was obtained in acceptable radiochemical yield, specific radioactivity and purity for evaluation in vitro. Autoradiographs of human brain obtained with [¹²⁵I]**8** showed radioactivity distribution according to known regional CB₁ receptor densities. Future research evaluating [¹²³I]**8** with SPECT imaging is therefore warranted.

Acknowledgments

S.R.D. and V.W.P. were supported by the Intramural Research Program of the National Institutes of Health, specifically the National Institute of Mental Health (NIMH), project number ZO1MH002793. We thank the NIMH Psychoactive Drug Screening Program (PDSP) for performing binding assays and Siv Eriksson for the excellent technical assistance with autoradiographic experiments. The PDSP is directed by Bryan L. Roth, PhD, with project officer Jamie Driscoll (NIMH) at the University of Carolina at Chapel Hill (contract NO1MH32004).




Figure 2. Autoradiographs from whole-hemisphere cryosections (panels A–D; 100 μm thickness) and cryosections (20 μm thickness) covering thalamus and brainstem (panels E and F) and temporal cortex (panels G and H) incubated with [¹²⁵I]**8** under baseline (panels A, C, E and G) and blocked (rimonabant, 10 μM; panels B, D, F and H) conditions. Abbreviations: Amg, amygdala; Ca, caudate nucleus; CG, cingulate gyrus; FC, frontal cortex; Hi, hippocampus; IGP, globus pallidus, internal segment; PC, parietal cortex; Pu, putamen; SN, substantia nigra; TC, temporal cortex; Th, thalamus.

Supplementary data

Supplementary data (experimental details of chemistry, labeling and autoradiography) associated with this article can be found, in the online version, at [doi:10.1016/j.bmcl.2009.08.092](https://doi.org/10.1016/j.bmcl.2009.08.092).

References and notes

1. Lambert, D. M. *J. Pharm. Belg.* **2001**, *56*, 111.
2. Devane, W. A.; Dysarz, F. A.; Johnson, M. R.; Melvin, L. S.; Howlett, A. C. *Mol. Pharmacol.* **1988**, *34*, 605.
3. Munro, S.; Thomas, K. L.; Abushaar, M. *Nature* **1993**, *365*, 61.
4. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G. *Pharmacol. Rev.* **2002**, *54*, 161.
5. Van Laere, K. *Eur. J. Nucl. Med. Mol. Imaging* **2007**, *34*, 1719.
6. Dean, B.; Sundram, S.; Bradbury, R.; Scarr, E.; Copolov, D. *Neuroscience* **2001**, *103*, 9.
7. Eggan, S. M.; Hashimoto, T.; Lewis, D. A. *Arch. Gen. Psychiatry* **2008**, *65*, 772.
8. Serra, G.; Fratta, W. *Clin. Pract. Epidemiol. Ment. Health* **2007**, *3*, 25.
9. Zavitsanou, K.; Garrick, T.; Huang, X. F. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2004**, *28*, 355.
10. Lynn, A. B.; Herkenham, M. *J. Pharmacol. Exp. Ther.* **1994**, *268*, 1612.
11. Gong, J. P.; Onaivi, E. S.; Ishiguro, H.; Liu, Q. R.; Tagliaferro, P. A.; Brusco, A.; Uhl, G. R. *Brain Res.* **2006**, *1071*, 10.
12. Yasuno, F.; Brown, A. K.; Zoghbi, S. S.; Krushinski, J. H.; Chernet, E.; Tauscher, J.; Schaus, J. M.; Phebus, L. A.; Chesterfield, A. K.; Felder, C. C.; Gladding, R. L.; Hong, J.; Halldin, C.; Pike, V. W.; Innis, R. B. *Neuropsychopharmacology* **2008**, *33*, 259.
13. Donohue, S. R.; Krushinski, J. H.; Pike, V. W.; Chernet, E.; Chesterfield, A. K.; Felder, C. C.; Halldin, C.; Schaus, J. M. *J. Med. Chem.* **2008**, *51*, 5833.
14. Donohue, S. R.; Halldin, C.; Schou, M.; Hong, J.; Phebus, L. A.; Chernet, E.; Hitchcock, S. A.; Gardinier, K. M.; Ruley, K. M.; Krushinski, J. H.; Schaus, J. M.; Pike, V. W. *J. Labelled Compd. Radiopharm.* **2008**, *51*, 149.
15. Finnema, S. J.; Donohue, S. R.; Zoghbi, S. S.; Brown, A. K.; Gulyás, B.; Innis, R. B.; Halldin, C.; Pike, V. W. *Synapse* **2009**, *63*, 22.
16. Burns, H. D.; Van Laere, K.; Sanabria-Bohorquez, S.; Hamill, T. G.; Bormans, G.; Eng, W. S.; Gibson, R.; Ryan, C.; Connolly, B.; Patel, S.; Krause, S.; Vanko, A.; Van Hecken, A.; Dupont, P.; De Lepeleire, I.; Rothenberg, P.; Stoch, S. A.; Cote, J.; Haggmann, W. K.; Jewell, J. P.; Lin, L. S.; Liu, P.; Goulet, M. T.; Gottesdiener, K.; Wagner, J. A.; de Hoon, J.; Mortelmans, L.; Fong, T. M.; Hargreaves, R. J. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 9800.
17. Liu, P.; Lin, L. S.; Hamill, T. G.; Jewell, J. P.; Lanza, T. J.; Gibson, R. E.; Krause, S. M.; Ryan, C.; Eng, W. S.; Sanabria, S.; Tong, X. C.; Wang, J. Y.; Levorse, D. A.; Owens, K. A.; Fong, T. M.; Shen, C. P.; Lao, J. L.; Kumar, S.; Yin, W. J.; Payack, J. F.; Springfield, S. A.; Hargreaves, R.; Burns, H. D.; Goulet, M. T.; Haggmann, W. K. *J. Med. Chem.* **2007**, *50*, 3427.
18. Donohue, S. R.; Pike, V. W.; Finnema, S. J.; Truong, P.; Andersson, J.; Gulyás, B.; Halldin, C. *J. Med. Chem.* **2008**, *51*, 5608.
19. Horti, A. G.; Fan, H.; Kuwabara, H.; Hilton, J.; Ravert, H. T.; Holt, D. P.; Alexander, M.; Kumar, A.; Rahmim, A.; Scheffel, U.; Wong, D. F.; Dannals, R. F. *J. Nucl. Med.* **2006**, *47*, 1689.
20. Fan, H.; Ravert, H. T.; Holt, D. P.; Dannals, R. F.; Horti, A. G. *J. Labelled Compd. Radiopharm.* **2006**, *49*, 1021.
21. Donohue, S. R.; Zoghbi, S.; Yasuno, F.; Terry, G.; Gourley, J.; Innis, R. B.; Halldin, C.; Pike, V. W. *Curr. Radiopharmaceuticals* **2008**, *1*, 93.
22. Laruelle, M.; Slifstein, M.; Huang, Y. *Mol. Imaging Biol.* **2003**, *5*, 363.
23. Waterhouse, R. N. *Mol. Imaging Biol.* **2003**, *5*, 376.
24. Hirst, R. A.; Almond, S. L.; Lambert, D. G. *Neurosci. Lett.* **1996**, *220*, 101.
25. Herkenham, M.; Lynn, A. B.; Johnson, M. R.; Melvin, L. S.; De Costa, B. R.; Rice, K. C. *J. Neurosci.* **1991**, *11*, 563.
26. Glass, M.; Dragunow, M.; Faull, R. L. *Neuroscience* **1997**, *77*, 299.